Ischaemia-reperfusion injury impairs tissue plasminogen activator release in man

Eur Heart J. 2012 Aug;33(15):1920-7. doi: 10.1093/eurheartj/ehr380. Epub 2011 Oct 11.

Abstract

Aims: Ischaemia-reperfusion (IR) injury causes endothelium-dependent vasomotor dysfunction that can be prevented by ischaemic preconditioning. The effects of IR injury and preconditioning on endothelium-dependent tissue plasminogen activator (t-PA) release, an important mediator of endogenous fibrinolysis, remain unknown.

Methods and results: Ischaemia-reperfusion injury (limb occlusion at 200 mmHg for 20 min) was induced in 22 healthy subjects. In 12 subjects, IR injury was preceded by local or remote ischaemic preconditioning (three 5 min episodes of ipsilateral or contralateral limb occlusion, respectively) or sham in a randomized, cross-over trial. Forearm blood flow (FBF) and endothelial t-PA release were assessed using venous occlusion plethysmography and venous blood sampling during intra-arterial infusion of acetylcholine (5-20 µg/min) or substance P (2-8 pmol/min). Acetylcholine and substance P caused dose-dependent increases in FBF (P<0.05 for all). Substance P caused a dose-dependent increase in t-PA release (P<0.05 for all). Acetylcholine and substanceP-mediated vasodilatation and substanceP-mediated t-PA release were impaired following IR injury (P<0.05 for all). Neither local nor remote ischaemic preconditioning protected against the impairment of substance P-mediated vasodilatation or t-PA release.

Conclusion: Ischaemia-reperfusion injury induced substanceP-mediated, endothelium-dependent vasomotor and fibrinolytic dysfunction in man that could not be prevented by ischaemic preconditioning.

Clinical trial registration information: Reference number: NCT00789243, URL: http://clinicaltrials.gov/ct2/show/NCT00789243?term=NCT00789243&rank=1.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Analysis of Variance
  • Blood Pressure / physiology
  • Constriction
  • Cross-Over Studies
  • Fibrinolysis / physiology
  • Forearm / blood supply
  • Humans
  • Ischemic Preconditioning / methods*
  • Male
  • Neurotransmitter Agents / pharmacology
  • Reperfusion Injury / complications*
  • Reperfusion Injury / metabolism
  • Substance P / pharmacology
  • Tissue Plasminogen Activator / metabolism*
  • Vasodilation / drug effects
  • Vasodilator Agents / pharmacology
  • Young Adult

Substances

  • Neurotransmitter Agents
  • Vasodilator Agents
  • Substance P
  • Tissue Plasminogen Activator
  • Acetylcholine

Associated data

  • ClinicalTrials.gov/NCT00789243